Yongning Jia1, K E Ji2, Jiafu Ji3, Chunyi Hao4, Lin Ye2, Andrew J Sanders2, Wen G Jiang5. 1. Cardiff China Medical Research Collaborative, Cardiff-Peking Cancer Institute, Cardiff University School of Medicine, Cardiff, U.K. Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital&Institute, Beijing, P.R. China. 2. Cardiff China Medical Research Collaborative, Cardiff-Peking Cancer Institute, Cardiff University School of Medicine, Cardiff, U.K. 3. Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital&Institute, Beijing, P.R. China. 4. Department of Hepato-Pancreatic Biliary Surgery, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, P.R. China. 5. Cardiff China Medical Research Collaborative, Cardiff-Peking Cancer Institute, Cardiff University School of Medicine, Cardiff, U.K. Jiangw@cf.ac.uk.
Abstract
BACKGROUND: Pancreatic cancer is hard to diagnose and treat due to its asymptomatic development and early metastasis. Supplementary therapy including molecular targeted therapy is needed to improve the outcome of pancreatic cancer. The significance of interleukin 24 (IL24) and its receptors in pancreatic cancer were investigated in this study. MATERIALS AND METHODS: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was carried out in 200 patient samples of pancreatic cancer. Transcript and protein expression were investigated in pancreatic cancer cells. Impact of IL24 recombinant protein on cell functions was examined. RESULTS: High IL20R1 transcript expression was related to early T stage, and advanced N, and M stage. They collectively correlated with the survival of the patients. Treatment with IL24 inhibited cell growth, but its impact on migration varied depending on protein concentration. CONCLUSION: IL20R1 correlated with prognosis of patients with pancreatic cancer, and mediates pancreatic cancer cell growth and migration. It may be a potential biomarker for IL24 molecular-targeted therapy. Copyright
BACKGROUND:Pancreatic cancer is hard to diagnose and treat due to its asymptomatic development and early metastasis. Supplementary therapy including molecular targeted therapy is needed to improve the outcome of pancreatic cancer. The significance of interleukin 24 (IL24) and its receptors in pancreatic cancer were investigated in this study. MATERIALS AND METHODS: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was carried out in 200 patient samples of pancreatic cancer. Transcript and protein expression were investigated in pancreatic cancer cells. Impact of IL24 recombinant protein on cell functions was examined. RESULTS: High IL20R1 transcript expression was related to early T stage, and advanced N, and M stage. They collectively correlated with the survival of the patients. Treatment with IL24 inhibited cell growth, but its impact on migration varied depending on protein concentration. CONCLUSION:IL20R1 correlated with prognosis of patients with pancreatic cancer, and mediates pancreatic cancer cell growth and migration. It may be a potential biomarker for IL24 molecular-targeted therapy. Copyright
Authors: Ravikanth Maddipati; Robert J Norgard; Timour Baslan; Komal S Rathi; Amy Zhang; Asal Saeid; Taku Higashihara; Feng Wu; Angad Kumar; Valli Annamalai; Saurav Bhattacharya; Pichai Raman; Christian A Adkisson; Jason R Pitarresi; Maximilian D Wengyn; Taiji Yamazoe; Jinyang Li; David Balli; Michael J LaRiviere; Tuong-Vi C Ngo; Ian W Folkert; Ian D Millstein; Jonathan Bermeo; Erica L Carpenter; John C McAuliffe; Maja H Oktay; Rolf A Brekken; Scott W Lowe; Christine A Iacobuzio-Donahue; Faiyaz Notta; Ben Z Stanger Journal: Cancer Discov Date: 2021-09-22 Impact factor: 38.272